Where does Immutrix Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Immutrix Therapeutics, Inc. ranks #19,894 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Immutrix Therapeutics, Inc. hold?

Immutrix Therapeutics, Inc. holds 14 US utility patents granted between 2016 and 2025, spanning 9 technology areas.

What is Immutrix Therapeutics, Inc.'s Innovation Score?

Immutrix Therapeutics, Inc. has an Innovation Score of 40.0 out of 100 (top 37% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Immutrix Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Immutrix Therapeutics, Inc.'s recent grant velocity is +167% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Immutrix Therapeutics, Inc.'s patents?

Immutrix Therapeutics, Inc.'s patents average 14.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Immutrix Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Immutrix Therapeutics, Inc.

Q: What technology areas does Immutrix Therapeutics, Inc. focus on?

Immutrix Therapeutics, Inc.'s top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 13 patents, ranking #542 of 3,490 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

USPTO PatentsView assignee record - 14 granted patents across 9 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Immutrix ranks #19,894 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 9 technology areas.

#19,894
of 49,997 US assignees by volume: Top 37%
by Innovation Score (40.0/100): 14.9
avg claims per patent: +167%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R19894 · US Corporation #19,894 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 14 grants
MID-PACK #19,894/49,997
PHOTO-FINISH Igneous Systems
CPC-NARROW A61M · 9 areas
INNOV-PAR 40.0/100
CLAIMS-RICH 14.9 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +167% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Igneous Systems, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Immutrix’s 40.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.4 pts (23%) Velocity 11.1 pts (28%) Breadth 10.6 pts (26%) Claim depth 9.0 pts (22%)

Qualcomm Incorporated · highest

85
Immutrix Therapeutics · this assignee

40
3D Lighting… · lowest

7

What this shows Immutrix's Innovation Score is 40.0/100 (top 37% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Immutrix?

Each dot is one of Immutrix’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Immutrix’s own 14.9 claims/patent is at or below the 19.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Immutrix vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Immutrix's grants concentrate

Immutrix Therapeutics, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 92.9% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2024 (3 grants) versus a trough of 1 in 2016. By volume, Immutrix sits between Izumi Products Company and Ingenio, LLC.

Immutrix's three-year grant acceleration

Immutrix Therapeutics, Inc. shows 5 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Izumi Products

14
Igneous Systems

14
Ikena Oncology

14
Imagine Scientific

14
Implant Direct Sy…

14
Incelldx

14
Ineoquesto

14
Ingenio

14
Immutrix Therapeu… ◀

14

What this shows Immutrix holds 14 patents at rank #19,919, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Immutrix

By rank, the assignees closest to #19,919 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Immutrix's primary technology class.

Immutrix's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 37% higher than 63% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Immutrix Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	7.1%
2017	1	7.1%
2018	1	7.1%
2020	2	14.3%
2021	1	7.1%
2023	2	14.3%
2024	3	21.4%
2025partial year	3	21.4%

Which technologies does Immutrix Therapeutics, Inc. patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 13

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 11

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

B01D - Separation 2

C01B - Non-metallic ELEMENTS; Compounds THEREOF; ; Metalloids OR Compounds Thereof NOT Covered BY Subclass C01c 1

C01P - Indexing Scheme Relating TO Structural AND Physical Aspects OF Solid Inorganic Compounds 1

C08J - WORKING-UP; General Processes OF COMPOUNDING; After-treatment NOT Covered BY Subclasses C08b, C08c, C08f, C08g or C08h 1

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Immutrix Therapeutics, Inc.'s patent record in context - here's where to go next.

Immutrix Therapeutics, Inc.'s lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 92.9% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #19,894 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Immutrix Therapeutics, Inc. against Izumi Products Company, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 40.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.